Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 8/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541653 | 1.00 | ATR (0.44) | ATRLCKCYP17A1KMT2AMEN1 | |
| SCHEMBL7969276 | 0.87 | LCK (0.40) | ATRLCKKMT2AMEN1NPC1 | |
| SCHEMBL10330649 | 0.86 | CYP17A1 (0.39) | ATRLCKCYP17A1KMT2AMEN1 | |
| SCHEMBL10270535 | 0.85 | LCK (0.39) | ATRLCKKMT2AMEN1NPC1 | |
| SCHEMBL10323025 | 0.83 | ATR (0.40) | ATRLCKCYP17A1KMT2AMEN1 | |
| SCHEMBL29951599 | 0.82 | L3MBTL1 (0.41) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL247107 | 0.82 | L3MBTL1 (0.41) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL30301479 | 0.79 | ATR (0.43) | ATRLCKCYP17A1KMT2AMEN1 | |
| SCHEMBL1514065 | 0.79 | MAPT (0.37) | KMT2AMEN1GAA | |
| SCHEMBL15335075 | 0.78 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009138176-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009007029-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008113469-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | ATR 883/4885LCK 53/4885CYP17A1 4085/4885 |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | ATR 259/4885LCK 54/4885CYP17A1 4584/4885 |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | ATR 661/4885LCK 40/4885CYP17A1 4532/4885 |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | ATR 4296/4885LCK 2628/4885CYP17A1 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.